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Abstract: Clinical management of tuberculosis (TB) in endemic areas is often challenged by a lack of
resources including laboratories for Mycobacterium tuberculosis (Mtb) culture. Traditional phenotypic
drug susceptibility testing for Mtb is costly and time consuming, while PCR-based methods are limited
to selected target loci. We herein utilized a portable, USB-powered, long-read sequencing instrument
(MinION), to investigate Mtb genomic DNA from clinical isolates to determine the presence of anti-TB
drug-resistance conferring mutations. Data analysis platform EPI2ME and antibiotic-resistance
analysis using the real time ARMA workflow, identified Mtb species as well as extensive resistance
gene profiles. The approach was highly sensitive, being able to detect almost all described drug
resistance conferring mutations based on previous whole genome sequencing analysis. Our findings
are supportive of the practical use of this system as a suitable method for the detection of antimicrobial
resistance genes, and effective in providing Mtb genomic information. Future improvements in the
error rate through statistical analysis, drug resistance prediction algorithms and reference databases
would make this a platform suited for the clinical setting. The small size, relatively inexpensive cost
of the device, as well as its rapid and simple library preparation protocol and analysis, make it an
attractive option for settings with limited laboratory infrastructure.
Keywords: next-generation sequencing; MinION; tuberculosis; drug resistance
1. Introduction
Tuberculosis (TB) is the number one cause of human death due to an infectious disease, with
1.7 million deaths per year worldwide [1]. The causative agents of TB are a group of closely related
bacteria known as the Mycobacterium tuberculosis (Mtb) complex (MTBC), which has been thought
to have low DNA sequence diversity [2]. This limited diversity, however, is influenced by selective
pressures and background selection [2]. Various human-adapted MTBC variants are known to differ in
virulence, progression of disease and transmission potential.
TB surveillance of highly-virulent and multi-drug resistant (MDR) strains is paramount for
adequate diagnosis and treatment [1,3]. Traditional phenotypic drug susceptibility testing (DST) through
culture-based methods has multiple caveats, amongst them being that TB culturing can take days
to weeks [4]. To reduce the time to obtain test results, alternative methods like real-time PCR-based
Xpert MTB/RIF testing have been recommended by the World Health Organization [5]. These methods,
however, are unable to detect drug-resistance mutations outside of the selected target loci [6], or they
can produce false positive results [7]. In addition, clinical management where TB risk is high is often
challenged by a lack of resources such as facilities for chest X-rays or laboratories for Mtb isolation
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and culture. To address these challenges, a whole-genome sequencing (WGS) approach can generate
antibiotic susceptibility profiles, detect MDR-TB, and discover other MTB virulence factors [3,4]. This
method, however, is also limited by resources, hospital–laboratory infrastructure and personnel training
in bioinformatic analysis. A hybridization-based system (reverse line probe assay) has been recently
proposed as an alternative in cost to WGS, but since this methodology is based on hybridization, it is
also limited to the genomic region of Mtb examined [8]. Furthermore, although the cost per sample is
much less than for other assays, it still requires laboratory equipment.
Development of a diagnostic assay that can be used at the point of care to rapidly and accurately
diagnose TB and to include multidrug-resistant tuberculosis (MDR-TB) or extensively drug-resistant
tuberculosis (XDR-TB) should be given a high priority. MDR-TB characterization typically requires
costly machinery and handling in a specialized reference laboratory, not to mention the time required
for shipping and processing the sample. A portable sequencing system that could be taken to the field,
would not only reduce the cost of TB testing, but will also speed up the diagnoses. A rapid direct
sample sequencing device would significantly reduce the time to obtain test results.
The MinION -Oxford Nanopore Technologies Limited (ONT), is a pocket sized (10 × 3 × 2 cm),
portable, USB-powered, long-read sequencing instrument [9]. Among the existing sequencing platforms,
it has the potential to be the best suited method to investigate the chain of transmission of TB and to
determine the susceptibility of anti-TB drugs in the near future. This platform is particularly useful
in remote settings or with limited infrastructure [9]. A careful evaluation of MinION as a potential
methodology for the surveillance of TB was first reported in 2017 [10]. In this investigation, authors
used both Illumina and ONT platforms for the diagnosis of Mtb infection. Utilization of the MinION
in this study was conducted only with simulated Mtb infection using Ziehl–Neelsen (ZN)-negative
sputum DNA combined with Mycobacterium bovis BCG strain DNA, not direct sputum sample. Despite
the advantage of a portable sequencer in MDR-TB testing, so far there is no peer-reviewed published
protocol of ONT-WGS based, rapid MDR-TB testing of patient sputum samples. It is unknown if
this portable DNA sequencing system would be effective in providing information on Mtb genotype,
drug-susceptibility in a sputum sample.
In this pilot study, we evaluated the performance of this portable sequence system for Mtb species
identification and detection of genes related to drug resistance, as a means of MDR-TB testing in a
diverse set of samples, including DNA isolated from sputum samples and from clinical microbiological
isolates.
2. Results
2.1. Identification of Mtb in Clinical Microbiological Isolates and Sputum Samples
Upon sequencing of a set of DNA obtained from various sources, utilizing the What’s In My Pot
(WIMP) app [11] we were able to identify Mtb in all samples evaluated in this study. It was evident
that DNA extracted directly from sputa yielded a great number of reads for human DNA (Table 1),
with only a few reads for Mtb. In contrast, the presence of reads assigned to Homo sapiens in clinical
isolates was minimal, and absent in the commercial Mtb genomic DNA.
2.2. Identification of Drug Resistance Conferring Mutations in DNA
We evaluated molecular genome-based drug resistance mutation analysis by sequencing DNA
samples using a portable, long-read sequencing platform. Sequenced and analyzed data from Mtb culture
isolates and commercially available Mtb genomic DNA showed numerous drug resistance-conferring
mutations (Table 2 and Appendix A, Appendix B, Appendix C, Appendix D, Appendix E, Appendix F,
Appendix G).
Comparison of the sequencing results of Mtb DNA obtained from direct sputum vs. those of
sequencing from Mtb DNA obtained from culture isolates, showed that the amount of reads for Mtb
was much higher from the latter samples (Table 2). The higher number of reads translated into a higher
number of resistance genes identified.
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Table 1. Microbial identification through sequencing DNA analysis. LAM: Latin American and




Mycobacterium tuberculosis Homo sapiens
HN878 Genomic DNA (bei-resources) 28,090 0
LAM Clinical isolate 8066 8
Beijing Clinical isolate 1772 2
410 Clinical isolate 6736 376
6548 Clinical isolate 9664 39
1766 Sputum 53 420,062
2836 Sputum 16 56,450
Data shown as cumulative reads.
Table 2. Mutations observed in drug resistance (DR) related genes through MinION and previous
whole genome analysis (WGA) sequencing analysis.
Samples Source
DR Related Genes Phenotypic
Resistance
ValidationMinion WGA a Detected byboth Systems
HN878 Genomic DNA (bei-resources) 33 0 - -
LAM Clinical isolate 20 N/A N/A N/A
Beijing Clinical isolate 32 N/A N/A N/A
410 Clinical isolate 34 5 4 3/4 b
6548 Clinical isolate 29 6 6 6/6
1766 Sputum 5 3 1 1/3
2836 Sputum 3 N/A N/A N/A
N/A: not available. a Ref 24 a One of the concordant hits among the sequencing experiments corresponded to the
embB gene, which has poor evidence of a correlation with phenotypic drug resistance; in accordance, the strain
was susceptible to ethambutol in vitro. Full description of the results is available in Appendix A, Appendix B,
Appendix C, Appendix D, Appendix E, Appendix F, Appendix G.
As pointed out previously, a limitation imposed by sequencing Mtb DNA from sputum samples
was the high proportion of human DNA. Despite this relatively low availability of Mtb DNA for
sequencing, it proved to be sufficient for obtaining a read coverage that allowed the identification of
drug resistance mutations (Table 2).
We then aimed to compare the results obtained for a subset of samples for which whole genome
analysis (WGA) data were available. Analyzing the MinION reads in real time with the ARMA pipeline
identified a larger number of mutations in genes related to drug resistance, which in some cases
included all, or the majority, of those identified by WGS analysis (Table 2). Most of the identified genes
had no or poor evidence of their involvement in clinically relevant drug resistance in TB (Appendix A,
Appendix B, Appendix C, Appendix D, Appendix E, Appendix F, Appendix G). For those genes with
moderate or high-level evidence for drug resistance prediction, some were not supported by the drug
susceptibility testing results (Table 2) or were redundant hits. For example, for isolate 6548, isoniazid
(INH) resistance was attributed to katG (also found in a previous WGA) but also to inhA and mutations
in the 16S rRNA gene were listed for amikacin, streptomycin and kanamycin resistance independently.
3. Discussion
In this study we have evaluated the genomic identification and drug mutation gene profiling
of Mtb isolates utilizing the MinION portable sequencer. Our findings endorse the need of further
research regarding the practical use of MinION for the detection and characterization of Mtb in clinical
isolates and in sputum samples. Our sample set consisted of Mtb genomic DNA obtained by different
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extraction methods. Recently, low-cost DNA extraction methods for Mtb WGS directly from patient
samples have been reported [10], allowing the bypass of laboratory equipment requirements for
genomic DNA obtainment.
The portable WGS-based detection system utilized here proved to be fast, relatively inexpensive,
with rapid and simple library preparation, and automated real-time analysis tools [10]. The most
innovative aspect of this sequencing system is its portability. Its small size and use of a USB port are
ideal as they reduce the infrastructure required for WGS sequencing, such as a climate-controlled
building, instead requiring only a laptop computer for the system to be operational [9,12].
The MinION has several advantages that make it uniquely suited for TB surveillance (Supplement
Table S1). Amongst its features, the MinION provides long-read sequencing data, which are ideal for
the detection of antimicrobial resistance genes [13], and some authors suggest that this can be achieved
even without the need of a high amount of reads [14]. The real time monitoring allows the analysis
of metagenomes from complex samples, which could save the 14 days of culture required for drug
susceptibility testing in TB. In our set of DNA samples obtained directly from sputum, the presence
of host DNA was far more abundant than Mtb DNA, but bacterial DNA could be discriminated and
drug resistance related genes were detected, albeit at low sequencing depth. Although identification at
the MTBC level provided by Xpert and other fast methods is usually enough for the diagnosis of TB,
direct species assignment from sputum samples is an advantage to highlight. Another big challenge in
the clinical setting is the bioinformatics analysis, as most clinical labs do not have trained personnel.
Real time antimicrobial resistance profiling is indeed, a crucial advantage to highlight. The steps from
raw data acquisition to analysis completion are fairly simple and easy to follow in their user-friendly
EPI2ME platform [15]. Furthermore, the analysis can be performed in real time even from the moment
data acquisition begins, potentially minimizing the results waiting time even more.
The number of mutations in drug resistance related genes overly surpassed those detected in
previous WGA. This may have several explanations. First, a high error rate has been acknowledged as a
limitation of Nanopore technology [16], thus, some of these could correspond to sequencing errors, in
spite of the overall accuracy of around 90%, according to the automated results. The initial high error
rates reported for the MinION [17], have improved over the past few years [18], currently over 95% raw
read accuracy and 99.9% consensus read accuracy is achievable. Incorporation of complementary short
read sequences [18], and the use of short DNA target sequences, circularized and then amplified via
rolling-circle amplification to produce high fidelity accurate repeats [19], are new proposed ways to
reduce the error rate. Additionally, recent statistical methods have been reported to aid in the accurate
detection of true mutations [20] Long read sequencing has a superior advantage over short read WGS
approach, especially in homopolymeric regions where indel is commonly used by bacteria as a drug
resistance strategy [21]. Therefore, although the higher number of drug resistance (DR) related genes
found in this study using MinION may be due in part a high error rate, it is also reasonable to think that
more genes were detected by the long read sequencing compared to the traditional short read WGS.
Further investigation is needed to clarify this. Additionally, it would be interesting to follow up on a
newer version (R10) of Nanopore’s Flowcell compared to the version used in this study (R9), as improved
accuracy with longer barrel and dual reader head in the sequencing pores shall provide better accuracy
especially in homopolymer regions. Alternatively, the higher number of detected DR genes by the
MinION could correspond to false positive hits detected by the automated ARMA pipeline. The WHO
endorses the use of next-generation sequencing analysis for drug-resistance profiling, only for a limited
number of genes (rpoB, katG and inhA for first line drugs and gyrA, gyrB, rss and eis promoters for second
line drugs) and for specific point mutations within them [16]. However, the reference database used by
the ARMA pipeline includes genes that lack empirical support for their clinical relevance in TB [16,22].
Almost half of the “hits” corresponded to this category (see Appendix A, Appendix B, Appendix C,
Appendix D, Appendix E, Appendix F, Appendix G), indicating that the reference database needs
further curation. In addition, some mutations in known resistance conferring genes could correspond to
polymorphisms with no functional impact depending on the mutated codon (this is not disclosed in the
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automated analysis) [16], which could explain the detection of resistance related genes in susceptible
isolates. The same could be said for genes like mtrA or AAC(2’)-IC, which were detected in 5 out of 7
isolates irrespective of their resistance profile and could correspond to polymorphisms.
Nevertheless, the sensitivity of the MinION sequencing for the detection of drug resistance
mutations was good. Isolates 410 and 6548 belong to the extensively studied MDR M strain [23,24]
which accumulated resistance to several drugs. The ARMA pipeline detected three of the four drug
resistance conferring mutations and an additional mutation in isolate 410, and all six resistance mutations
of isolate 6548. Interestingly, the gidB mutation, which confers resistance to streptomycin, is not the most
frequent among clinical isolates but is characteristic of this cluster and was acquired four decades ago
when the expansion of this cluster began [24]. In addition, a rifampicin resistance conferring mutation
was found in the metagenome of the sputum sample 1766, which belongs to the Ra cluster, another
conspicuous MDR strain of Argentina [25]. These phenotypically confirmed drug-resistance conferring
mutations were identified with two to 17 reads depending on the gene, with similar accuracy values.
This indicates that although it is usually regarded a critical variable in the analysis of next-generation
sequencing data, sequencing depth was not the main constraint in our work. Prompt and accurate
information on Mtb strains would have implications for management to minimize transmission of
drug-resistant TB and start the most appropriate TB control and anti-TB therapy. Various phylogenetic
lineages of the Mtb complex are distributed differently around the world [2]. In Latin America, both
drug susceptible and drug resistant TB are mainly related to the Euro–American Lineage [26–29] and
the Beijing strain has a minor impact, in contrast to what is reported in other regions. Drug resistance
databases mostly rely on the genome H37Rv strain. It is interesting to challenge this sequencing system
with samples sets with diverse genetic backgrounds like ours to assess its impact in the performance.
Overall, our findings indicate that the improvements in the future should focus on: (1) recovering
higher number of reads corresponding to Mtb from sputa; (2) lowering MinION sequencing error rates;
(3) improving the drug-resistance conferring mutation detection algorithms for automated analysis
and (4) curating the reference database to include only those hits that have a strong correlation with
Mtb drug resistance phenotype.
Although our data relies on a short number of DNA samples, our findings suggest that this
portable DNA sequencing system could be effective in reducing time and providing information on
Mtb genotype and drug-susceptibility from direct sputum samples. As larger studies—evaluating
parameters such as the minimal number of reads for a complete reliable drug susceptibility profiling,
optimization in software and database accuracy for the prediction of new drug resistance genes, and
reduction in false positive drug detection—are conducted, this system could potentially revolutionize
current TB testing procedures, especially in genomic surveillance for MDR-TB in the clinical setting.
4. Materials and Methods
4.1. Mtb Genomic DNA
Mtb genomic DNA, strain HN878 was acquired through bei resources (NR-14867). Genomic
bacterial DNA extracted from four laboratory cultured Mtb isolates from sputum samples was also
utilized (Table 1). These correspond to a strain belonging to the Beijing lineage, a strain belonging to
the Latin American and Mediterranean (LAM) lineage [27], and two closely related strains belonging
to the Haarlem lineage, the so called M strain (isolate 6548), and an M strain variant (isolate 410).
Genomic DNA was also extracted directly from 2 sputum samples from pulmonary TB patients
with positive bacilloscopy scored through correspondent acid-fast bacteria (AFB) smears. These latter
samples included a strain susceptible to the first line drugs INH, RIF, STR, EMB (sample 2836) and an
Ra strain (sample 1766) which along with the M strain constitute the most prevalent MDR clusters in
Argentina [30]. MPureTM DNA Extraction Kit (MP Biomedical), as well as inactivation and lysis by
sonication protocol [27] were used for bacterial DNA extraction, except for DNA from strain HN878,
which used a delipidation method, followed by lysozyme, RNase, SDS and proteinase digestion [31].
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4.2. Whole Genome Sequencing (WGS) Data
Whole genome sequencing (WGS) with Illumina was available for isolates 6548 and 410 [23]
and for representative isolates of the Ra cluster for comparison with sputum sample 1766 [22]. WGS
data from Mtb was obtained by eliminating human DNA sequences utilizing “Read Until” approach
(OMICtools) for target sequencing [32]. Mtb identification was performed once the metagenome
was obtained.
4.3. MinION DNA Sequencing and Resistance Gene Identification
DNA sample libraries were constructed using Rapid Sequencing Kit (ONT, Littlemore, UK), and
sequencing was conducted on MinION-compatible R9.4 flow cells (ONT, UK). Primary data acquisition
was done using MinKNOW, the operating software that drives nanopore sequencing devices. Raw data
were processed for basecalling via Albacore. Data were then further processed using the cloud-based
data analysis platform EPI2ME [15]. Microbial species identification was done using the What’s In My
Pot (WIMP) analysis workflow [11], and detection of mutations conferring antibiotic drug resistance
was done through the real time antimicrobial resistance mapping application (ARMA) [33].
5. Conclusions
In this study we have evaluated the genomic identification and drug mutation gene profiling of
Mtb isolates utilizing the MinION portable sequencer The approach was highly sensitive, being able to
detect almost all described drug resistance conferring mutations based on previous whole genome
sequencing analysis. Our findings are supportive of the practical use of this system as a suitable method
for the detection of antimicrobial resistance genes, and effective in providing Mtb genomic information.
Future improvements in the error rate through statistical analysis, drug resistance prediction algorithms
and reference databases would make this a platform suited for the clinical setting. The small size,
relatively inexpensive cost of the device, as well as its rapid and simple library preparation protocol
and analysis, make it an attractive option for settings with limited laboratory infrastructure.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/9/548/s1,
Table S1: Comparison of MinION based TB surveillance and current probe based or culture-based methods.
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DR GENE Drug Comments 1 Reads Accuracy
Drug resistance related genes
1 rpoB RIF Strong evidence for rifampicin resistance 138 90.8
2 gyrA FLQ Strong evidence. Most commonly associated with FLQ resistance 110 90.8
3 ethA ETH Low level evidence 107 91.3
4 gidB STR Low level evidence for strains other than the M strain 88 90.9
5 katG INH Strong evidence for high level resistance to INH 84 90.5
6 inhA INH Strong evidence for low level resistance to INH 74 91.3
7 pncA PZA Strong evidence for pyrazinamide resistance 73 91.5
8 embA EMB Prom -12 related to ethambutol R but not enough evidence 73 90.7
9 tlyA Capreo Related to capreomycin resistance 69 90.8
10 embB EMB Most frequently found mutation, but not enough evidence for clinical use 68 91.5
11 kasA INH Not a frequent mutation conferring gene, low level of evidence 63 90.7
12 rpsL STR Strong evidence for STR resistance 58 91
13 16S rRNA STR Frequently found for STR R (in nt different from 2nd line injectables) 32 90.9
14 16S rRNA KAN Strong evidence for resistance to all 3 2nd line injectables 27 90.4
15 16S rRNA AMK Strong evidence for resistance to all 3 2nd line injectables 20 90.3
16 gyrB FLQ Strong evidence, related to FLQ resistance 77 90.9
17 embC EMB Related to ethambutol resistance but not enough evidence for clinical use 60 90.5
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No evidence for involvement in clinically relevant drug resistance
18 efpA efflux pump No evidence of involvement in drug resistant phenotype 93 91.3
19 embR EMB No evidence of involvement in drug resistant phenotype 82 91.1
20 AAC(2’)-Ic EMB No evidence of involvement in drug resistant phenotype 75 92
21 ndh INH No evidence of involvement in drug resistant phenotype 74 90.9
22 iniA EMB Induced by drugs but role in resistance unclear 74 91.9
23 Erm(37) - No evidence of involvement in drug resistant phenotype 70 90.9
24 mtrA - No evidence of involvement in drug resistant phenotype 69 91.3
25 mfpA - No evidence of involvement in drug resistant phenotype 67 91.3
26 tsnr - No evidence of involvement in drug resistant phenotype 66 89.8
27 drrA - No evidence of involvement in first or second line drug resistance 63 92.2
28 iniC EMB Induced by drugs but role in resistance unclear 57 91
29 drrC - No evidence of involvement in first or second line drug resistance 45 91.9
30 murA - No evidence of involvement in drug resistant phenotype 44 90.3
31 drrB - No evidence of involvement in first or second line drug resistance 36 92.5
32 arabinosyltransferase - No evidence of involvement in drug resistant phenotype 31 92.6
33 16S rRNA Viomycin Not a 1st or 2nd line drug for TB 27 90
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch 2016 Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/handle/
10665/274443; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol, ETH: ethinamide, FLQ: fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF: rifampicin,
STR: streptomycin, TB: tuberculosis.
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Appendix B
Specimen: Culture isolate
DR Status Susceptible Resistance Profile: PanS
Strain LAM Family Strain
MinION
DR GENE Drug Comments 1 Reads Accuracy
Drug resistence related genes
1 embA EMB prom -12 related to ethambutol R but not enough evidence 5 86.3
2 embC EMB Related to ethambutol resistance but not enough evidence for clinical use 3 89
3 tlyA Capreo Related to capreomycin resistance 2 82.7
4 embB EMB Most frequently found mutation, but not enough evidence for clinical use 2 88.2
5 rpoB RIF strong evidence for rifampicin resistance 2 89.3
6 gyrB FLQ Strong evidence, related to FLQ resistance 2 91.3
7 ethA ETH Low level evidence 2 95.4
8 katG INH Strong evidence for high level resistance to INH 1 91.9
9 rpsL STR Strong evidence for STR resistance 1 90.3
10 kasA INH Not a frequent mutation conferring gene, low level of evidence 1 91.9
No evidence for involvement in clinically relevant drug resistance
11 mtrA - No evidence of involvement in drug resistant phenotype 3 91
12 murA - No evidence of involvement in drug resistant phenotype 2 87.8
13 AAC(2’)-Ic - No evidence of involvement in drug resistant phenotype 2 87.8
14 ndh INH No evidence of involvement in drug resistant phenotype 2 83.6
15 iniA EMB Induced by drugs but role in resistance unclear 2 85.7
16 iniC EMB Induced by drugs but role in resistance unclear 2 87.4
17 embB RIF Not related to RIF R 2 91.8
18 tsnr - No evidence of involvement in drug resistant phenotype 1 85
19 embR EMB No evidence of involvement in drug resistant phenotype 1 85.8
20 arabinosyltransferase - No evidence of involvement in drug resistant phenotype 1 89.4
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch 2016 Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/handle/
10665/274443; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol, ETH: ethinamide, FLQ: fluoroquinolones, H/INH: isoniazid, KAN: kanamycin, Z/PZA: pyrazinamide, R/RIF:
rifampicin, S/STR: streptomycin.




Strain: Beijing family strain
MinION
DR GENE Drug Comments 1 Reads Accuracy
Drug resistance related genes
1 embA EMB prom -12 related to ethambutol R but not enought evidence 23 87.8
2 rpoB RIF strong evidence for rifampicin resistance 20 88.4
3 embB EMB Most frequently found mutation, but not enough evidence for clinical use 13 87
4 kasA INH Not a frequent mutation conferring gene, low level of evidence 11 90.8
5 gyrB FLQ Strong evidence, related to FLQ resistance 9 88.4
6 gyrA FLQ Strong evidence. Most commonly associated with FLQ resistance 8 88.6
7 katG INH Strong evidence for high level resistance to INH 7 86.1
8 ethA ETH Low level evidence 7 92
9 embC EMB Related to ethambutol resistance but not enough evidence for clinical use 6 90.5
10 tlyA Capreo Related to capreomycin resistance 6 87.5
11 inhA INH Strong evidence for low level resistance to INH 6 89.6
12 gidB STR Low level evidence for strains other than the M strain 3 91.4
13 pncA PZA strong evidence for pyrazinamide resistance 1 97.5
14 rpsL STR Strong evidence for STR resistance 1 91.6
15 16S rRNA AMK Strong evidence for resistance to all 3 2nd line injectables 1 87.3
No evidence for involvement in clinically relevant drug resistance
16 murA - No evidence of involvement in drug resistant phenotype 10 86.4
17 efpA efflux pump No evidence of involvement in drug resistant phenotype 7 90.6
18 drrA - No evidence of involvement in first or second line drug resistance 7 86.5
19 ndh INH No evidence of involvement in drug resistant phenotype 7 92.6
20 embR EMB No evidence of involvement in drug resistant phenotype 6 92
21 Erm(37) - No evidence of involvement in drug resistant phenotype 5 90.3
22 drrC - No evidence of involvement in first or second line drug resistance 5 89.9
23 drrB - No evidence of involvement in first or second line drug resistance 5 86.5
24 mfpA - No evidence of involvement in drug resistant phenotype 4 88.7
25 mtrA - No evidence of involvement in drug resistant phenotype 4 89
26 iniA EMB Induced by drugs but role in resistance unclear 4 93.7
27 iniC EMB Induced by drugs but role in resistance unclear 4 89.4
28 tsnr - No evidence of involvement in drug resistant phenotype 3 86.4
29 AAC(2’)-Ic - No evidence of involvement in drug resistant phenotype 2 87.2
30 arabinosyltransferase - No evidence of involvement in drug resistant phenotype 2 91.1
31 EF-Tu Elfamycin Not a 1st or 2nd line drug for TB 1 74.3
32 16S rRNA Viomycin Not a 1st or 2nd line drug for TB 1 84.8
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch 2016 Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/handle/
10665/274443; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol, ETH: ethinamide, FLQ: fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF: rifampicin,
STR: streptomycin.
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Appendix D
Sample: 410 Specimen: Isolate
DR Status: MDR Resistance profie: INH, RIF, STR, PZA
Strain: M strain-variant
MinION WGA 2
DR GENE Drug Comments 1 READS Accuracy Mutation MinION vs. WGA DR Phenotype MinION vs. Phenotype
Drug resistence related genes
1 kasA INH Not a frequent mutation conferring gene, low level of evidence 20 89.2 wt discordant R -
2 gyrA FLQ Strong evidence. Most commonly associated with FLQ resistance 16 91.6 wt discordant S discordant
3 rpoB RIF strong evidence for rifampicin resistance 16 89.3 H526L 4 concordant R concordant
4 pncA PZA strong evidence for pyrazinamide resistance 14 91 Y103D concordant R concordant
5 gidB STR V100fs is a unique mutation found in M strain lineage 3 14 89.7 V100fs concordant R concordant
6 tlyA Capreo Related to capreomycin resistance 13 91 wt discordant S discordant
7 rpsL STR Strong evidence for STR resistance 12 92.6 wt discordant - -
8 inhA INH Strong evidence for low level resistance to INH 12 91.6 wt discordant - -
9 gyrB FLQ Strong evidence, related to FLQ resistance 10 89.9 wt discordant S discordant
10 ethA ETH Low level evidence 10 88.1 wt discordant S discordant
11 embB EMB Most frequently found mutation, but not enough evidence for clinical use 7 88.7 wt discordant S discordant
12 embC EMB Related to ethambutol resistance but not enough evidence for clinical use 6 89.4 V981L concordant S no strong evidence ofgenotype-phenotype correlation
13 embA EMB prom -12 related to ethambutol R but not enought evidence 5 89 wt discordant S discordant
14 16S rRNA STR Frequently found for STR R (in nt different from 2nd line injectables) 4 89.4 wt discordant S discordant
15 16S rRNA AMK Strong evidence for resistance to all 3 2nd line injectables 3 91.1 wt discordant S discordant
16 16S rRNA KAN Strong evidence for resistance to all 3 2nd line injectables 3 88.3 wt discordant S discordant
17 katG INH Strong evidence for high level resistance to INH undetected - S315T discordant R discordant (gene undetected)
No evidence for involvement in clinically relevant drug resistance
18 mtrA - Not related to DR 19 87.9 wt discordant - -
19 iniA EMB Induced by drugs but role in resistance unclear 16 88.3 wt discordant - -
20 tsnr - Not related to DR 16 88.5 wt discordant - -
21 Erm(37) - Not related to DR 15 87.9 wt discordant - -
22 mfpA - Not related to DR 15 90.9 wt discordant - -
23 embR EMB No evidence of involvement in drug resistant phenotype 13 89.6 wt discordant - -
24 efpA efflux pump No evidence of involvement in drug resistant phenotype 11 90.5 wt discordant - -
25 AAC(2’)-Ic - Not related to DR 10 89.5 wt discordant - -
26 drrA - No evidence of involvement in first or second line drug resistance 10 91.4 wt discordant - -
27 ndh INH No evidence of involvement in drug resistant phenotype 9 89.7 wt discordant - -
28 mur A - No evidence of involvement in drug resistant phenotype 8 87.5 wt discordant - -
29 drrC - No evidence of involvement in first or second line drug resistance 5 93 wt discordant - -
30 iniC EMB Induce by drugs but role in resistance unclear 4 86.5 wt discordant - -
31 16S rRNA viomycin Not a 1st or 2nd line drug for TB 4 92.1 wt discordant - -
32 drrB - No evidence of involvement in first or second line drug resistance 3 92.2 wt discordant - -
33 embB RIF Not related to RIF R 3 91.1 wt discordant - -
34 RbpA - Not related to DR in Mtb 2 79.5 wt discordant - -
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch, 2016, Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/
handle/10665/274443; 2 Bigi et al. 2017 Tuberculosis (Edinb.) 103 28-36; 3 Eldhom et al. 2015 Nature Comm; 4 E. coli annotation; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol,
ETH: ethinamide, FLQ: fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF: rifampicin, STR: streptomycin. R: resistant, S: susceptible; Bold letters correspond to
drug resistance related mutations previously found in 410 strain.
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Appendix E
Sample: 6548 Specimen: isolate
DR Status: Pre-XDR Resistance profie: INH, RIF, STR, PZA, EMB, KAN
Strain: M strain
MinION WGA 2
DR GENE Drug Comments 1 READS Accuracy Mutation MinION vs. WGA DR Phenotype MinION vs. Phenotype
Drug resistence related genes
1 rpoB RIF strong evidence for rifampicin resistance 17 91.1 S531L 4 concordant R concordant
2 embA EMB prom -12 related to ethambutol R but not enought evidence 15 92.8 wt discordant - -
3 kasA INH Not a frequent mutation conferring gene, low level of evidence 15 89.8 wt discordant - -
4 katG INH Strong evidence for high level resistance to INH 13 90.5 S315T concordant R concordant
5 ethA ETH Low level evidence 13 91.2 wt discordant NA -
6 gyrA FLQ Strong evidence. Most commonly associated with FLQ resistance 13 92.2 wt discordant S discordant
7 inhA INH Strong evidence for low level resistance to INH 12 90 wt discordant - -
8 gidB STR V100fs is a unique mutation found in M strain lineage 3 12 90.7 V100fs concordant R concordant
9 pncA PZA strong evidence for pyrazinamide resistance 12 88.6 Q10P concordant R concordant
10 rpsL STR Strong evidence for STR resistance 11 90.3 wt discordant - -
11 embC EMB Related to ethambutol resistance but not enough evidence for clinical use 9 89.2 wt discordant - -
12 tlyA Capreo Related to capreomycin resistance 7 90.2 wt discordant NA -
13 embB EMB Most frequently found mutation, but not enough evidence for clinical use 6 91.6 G406A concordant R concordant
14 16S rRNA AMK Strong evidence for resistance to all 3 2nd line injectables 6 91.2 a1401g concordant NA -
15 16S rRNA STR Frequently found for STR R (in nt different from 2nd line injectables) 6 90 a1401g discordant - -
16 16S rRNA KAN Strong evidence for resistance to all 3 2nd line injectables 3 85.9 a1401g concordant R concordant
No evidence for involvement in clinically relevant drug resistance
17 iniA EMB Induced by drugs but role in resistance unclear 16 90 wt discordant - -
18 efpA efflux pump No evidence of involvement in drug resistant phenotype 15 91 wt discordant - -
19 ndh INH No evidence of involvement in drug resistant phenotype 14 91.3 wt discordant - -
20 mtrA - Not related to DR 14 89.5 wt discordant - -
21 tsnr - Not related to DR 14 91.2 wt discordant - -
22 iniC EMB Induce by drugs but role in resistance unclear 13 89.2 wt discordant - -
23 Erm(37) Not related to DR 13 89.7 wt discordant - -
24 AAC(2’)-Ic - Not related to DR 12 92 wt discordant - -
25 mfpA - Not related to DR 12 90.3 wt discordant - -
26 drrA - No evidence of involvement in first or second line drug resistance 12 89.8 wt discordant - -
27 drrB - No evidence of involvement in first or second line drug resistance 9 91.5 wt discordant - -
28 drrC - No evidence of involvement in first or second line drug resistance 8 91.4 wt discordant - -
29 RbpA - Not related to DR in Mtb 1 86.1 wt discordant - -
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch, 2016, Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/
handle/10665/274443; 2 Bigi et al. 2017 Tuberculosis (Edinb.) 103 28–36; 3 Eldhom et al. 2015 Nature Comm; 4 E. coli annotation; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol,
ETH: ethinamide, FLQ: fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF: rifampicin, STR: streptomycin. R: resistant, S: susceptible; Bold letters correspond to
drug resistance related mutations found in M strain.
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Appendix F
Sample: 1766 Specimen: sputum
DR Status: MDR Resistance profie: INH, RIF, PZA
Strain: Ra strain
MinION WGA 2
DR GENE Drug Comments 1 READS Accuracy Mutation MinION vs. WGA3 DR Phenotype MinION vs. Phenotype
Drug resistence related genes
1 rpoB RIF strong evidence for rifampicin resistance 2 75.3 S531L 3 concordant R concordant
2 rrs STR Frequently found for STR R (in nt different from 2nd line injectables) 2 79.1 wt discordant S discordant
3 katG INH Strong evidence for high level resistance to INH undetected - S315T - R discordant (gene not found)
4 pncA PZA strong evidence for pyrazinamide resistance undetected - S104R - R discordant (gene not found)
No evidence for involvement in clinically relevant drug resistance
5 tsnr - Not related to DR 1 95.3 - - - -
6 AAC(2’)-Ic - Not related to DR 1 92.1 - - - -
4 iniA EMB Induced by drugs but role in resistance unclear 1 88 - - - -
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch, 2016, Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/
handle/10665/274443; 2 Brynildsrud et al. 2018 Sci Advances (10.1126/sciadv.aat5869); 3 E. coli annotation; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol, ETH: ethinamide, FLQ:
fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF: rifampicin, STR: streptomycin. R: resistant, S: susceptible; Bold letters correspond to drug resistance related
mutations found in Ra strain.
Appendix G
Sample: 2836 Specimen: sputum
DR Status: Susceptible to INH, RIF, STR, EMB
Strain: unknown
MinION WGA
DR GENE drug Comments 1 READS Accuracy Mutation DR Phenotype MionION vs. Phenotype
Drug resistence related genes
1 inhA INH Strong evidence for low level resistance to INH 1 93.1 N/A S discordant
2 rpsL STR Strong evidence for STR resistance 1 88.6 N/A S discordant
No evidence for involvement in clinically relevant drug resistance
3 parC FLQ Absent in Mtb 1 87.8 - - -
1 Relevance in DR was checked in mycobrowser.epfl.ch, in Boritsch and Brosch, 2016, Microbiology spectrum (10.1128/microbiolspec.TBTB2-0020-2016) and https://apps.who.int/iris/
handle/10665/274443; AMK: amikacin, Capreo: capreomycin, EMB: ethambutol, ETH: ethinamide, FLQ: fluoroquinolones, INH: isoniazid, KAN: kanamycin, PZA: pyrazinamide, RIF:
rifampicin, STR: streptomycin. S: susceptible. N/A: not available.
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